The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2023 | The diagnostic and prognostic value of mass spectrometry in multiple myeloma
Noemí Puig, MD, PhD, University Hospital Salamanca, Salamanca, Spain, discusses the important role of mass spectrometry in multiple myeloma, and highlights the advantages of this method versus other conventional methods, based on studies conducted by the Spanish Myeloma Group. Dr Puig explains the higher sensitivity associated with mass spectrometry compared to serum protein electrophoresis and immunofixation, and further discusses the prognostic value of mass spectrometry. To conclude, Dr Puig compares the use of mass spectrometry to next-generation flow (NGF). This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
